Advanced search
Publication Cover
Expert Review of Vaccines Volume 3, 2004 - Issue 6
Submit an article Journal homepage
49
Views
30
CrossRef citations to date
0
Altmetric
Review

Preventative and therapeutic vaccines for fungal infections: from concept to implementation

George S Deepe Jr University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati, Ohio 45267-0560, USA. [email protected]
Pages 701-709 | Published online: 09 Jan 2014

References

  • Pappagianis D. Evaluation of the protective efficacy of the killed Coccidioides irnrnitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am. Rev. Respir. Dis. 148(3), 656–660 (1993).
  • Barnato AE, Sanders GD, Owens DK. Cost effectiveness of a potential vaccine for Coccidioides irnrnitis. Ernerg. Infect. Dis. 7(5), 797–806 (2001).
  • Smith JM, Griffin JE Strategies for the development of a vaccine against ringworm. J. Med. Vet. MycoL 33(2), 87–91 (1995).
  • Gudding R, Naess B, Aamodt 0. Immunization against ringworm in cattle. Vet. Rec. 128(4), 84–85 (1991).
  • Slavin M, Fastenau J, Sukarom I et aL Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. hat. J. Infect. Dis. 8(2), 111–120 (2004).
  • Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect. Dis. 3(12), 772–785 (2003).
  • Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39(3), 309–317 (2004).
  • Edwards J. Candida Species. In: Principles and Practice of Infectious Diseases, Volume 2. 5th Edition. Mandell GL, Dolin R (Eds). Churchill Livingstone, PA, USA, 2656–2674 (2000).
  • Burnie J, Matthews R. The role of antibodies against HSP90 in the treatment of fungal infections. Drug News Perspect. 16(4), 205–210 (2003).
  • De Bernardis F, Boccanera M, Adriani D et al. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. II771771117. 65(8), 3399–3405 (1997).
  • Matthews RC, Rigg G, Hodgetts S et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antirnicrob. Agents Chentother. 47 (7), 2208–2216 (2003).
  • •Demonstrates the efficacy of the monoclonal antibody to HSP90 from C. albicans.
  • Matthews R, Burnie J. The role of HSP90 in fungal infection. Immunol. Today13 (9), 345–348 (1992).
  • Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect. II771771117. 63(7), 2714–2719 (1995).
  • Han Y, Ulrich MA, Cutler JE. Candida albicansmannan extract—protein conjugates induce a protective immune response against experimental candidiasis. J Infect. Dis. 179(6), 1477–1484 (1999).
  • Han Y, Riesselman MH, Cutler JE. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. II771771117. 68(3), 1649–1654 (2000).
  • Han Y, Cutler JE. Assessment of a mouse model of neutropenia and the effect of an anticandidiasis monoclonal antibody in these animals. J Infect. Dis. 175(5), 1169–1175 (1997).
  • Burnie J, Matthews R. Genetically recombinant antibodies: new therapeutics against candidiasis. Expert Opin. Biol. Ther. 4(2), 233–241 (2004).
  • Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 22(7), 865–871 (2004).
  • Polonelli L, Seguy N, Conti S et al. Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin. Diagn. Lab. I17717711fla 4(2), 142–146 (1997).
  • Forleo-Neto E, de Oliveira CF, Maluf EM et al. Decreased point prevalence of Haernophilus intluenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria—tetanus toxoids—pertussis vaccine. J. Infect. Dis. 180(4), 1153–1158 (1999).
  • Chang YC, Kwon-Chung KJ. Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. j Bacteriol. 181(18), 5636–5643 (1999).
  • Perfect JR. Cryptococcosis. Infect. Dis. N. Arn. 3(1), 77–102 (1989).
  • Goldman DL, Khine H, Abadi J et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107(5), E66 (2001).
  • Mukherjee J, Pirofski LA, Scharff MD, Casadevall A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl Acad. Sci. (USA) 90 (8), 3636–3640 (1993).
  • Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformansglucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chentother. 38(3), 580–587 (1994).
  • Domer JE, Murphy JVV, Deepe GS Jr, Franco M. Immunomodulation in the mycoses. J Med. Vet. Mycol. 30 (Suppl. 1), 157–166 (1992).
  • Sanford JE, Lupan DM, Schlageter AM, Kozel TR. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58 (6), 1919–1923 (1990).
  • Nussbaum G, Cleare W, Casadevall A, Scharff MD, Valadon P Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp. Med. 185(4), 685–694 (1997).
  • Beenhouwer DO, Shapiro S, Feldmesser M, Casadevall A, Scharff MD. Both Thl and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect. II771771117. 69(10), 6445–6455 (2001).
  • Yuan RR, Casadevall A, Oh J, Scharff MD. T-cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl Acad. Sci. (USA,) 94(6), 2483–2488 (1997).
  • Taborda CP, Rivera J, Zaragoza 0, Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. j Irnmunol. 170(7), 3621–3630 (2003).
  • •Demonstrates that antibody efficacy in vivo is dependent, in part, on the amount that is injected.
  • Mukherjee J, Nussbaum G, Scharff MD, Casadevall A. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. Exp. Med. 181(1), 405–409 (1995).
  • Lendvai N, Casadevall A. Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: mechanism and relationship to antibody isotype. J Infect. Dis. 180(3), 791–801 (1999).
  • Nussbaum G, Anandasabapathy S, Mukherjee J et al. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice. Infect. Immun. 67(9), 4469–4476 (1999).
  • Fleuridor R, Lees A, Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. j I17717711fla 166(2), 1087–1096 (2001).
  • Pirofski LA. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens. Trends Microbiol. 9(9), 445–451 (2001).
  • Rosas AL, Nosanchuk JD, Casadevall A. Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect. II771771117. 69(5), 3410–3412 (2001).
  • Biondo C, Beninati C, Delfino D et al. Identification and cloning of a cryptococcal deacetylase that produces protective immune responses. Infect. Immun. 70(5), 2383–2391 (2002).
  • Biondo C, Beninati C, Bombaci M et al. Induction of T-helper Type 1 responses by a polysaccharide deacetylase from Cryptococcus neoformans. Infect. Immun. 71(9), 5412–5417 (2003).
  • Murphy JW, Schafer F, Casadevall A, Adesina A. Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans. Infect. II771771117. 66(6), 2632–2639 (1998).
  • Mansour MK, Yauch LE, Rottman JB, Levitz SM. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect. Immun. 72 (3), 1746–1754 (2004).
  • Mansour MK, Schlesinger LS, Levitz SM. Optimal T-cell responses to Cryptococcus neoforrnansmannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors. J Immunol. 168(6), 2872–2879 (2002).
  • Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl. J Med. 346(4), 225–234 (2002).
  • Anaissie EJ, Stratton SL, Dignani MC et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin. Infect. Dis. 34(6), 780–789 (2002).
  • Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes.' Clin. Invest. 69 (3), 617–631 (1982).
  • Ito JI, Lyons JM. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect. Dis. 186(6), 869–871 (2002).
  • Bozza S, Gaziano R, Lipford GB et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect. 4(13), 1281–1290 (2002).
  • Feldmesser M. Immune sera inhibit germination of Aspergillus formgatus conidia in vitro. 15th Meeting of the International Society of Human and Animal Mycology 25–29 May, TX, USA. Abstract 418 (2003).
  • Mycology, San Antonio, Texas, Abstract No. 418, May 25–29,2003. (2003).
  • Bozza S, Perruccio K, Montagnoli C et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood102 (10), 3807–3814 (2003).
  • ••Demonstrates the utility of dendritic cellvaccines for the treatment of aspergillosis in a model of stem cell transplantation.
  • Bozza S, Montagnoli C, Gaziano R et al. Dendritic cell-based vaccination against opportunistic fungi. Vaccine 22(7), 857–864 (2004).
  • Stevens DA, Schwartz HJ, Lee JY et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl. J. Med. 342(11), 756–762 (2000).
  • Deepe GS Jr. Histoplasma capsulatum. In: Principles and Practice of Infectious Diseases, Volume 2. 5th Edition. Mandell GL, Dolin R. Churchill Livingstone, PA, USA, 2718–2732 (2000).
  • Garcia JP, Howard DH. Characterization of antigens from the yeast phase of Histoplasrna capsulaturn. Infect. Immun. 4(2), 116–125 (1971).
  • Tewari RP, Sharma D, Solotorovsky M, Lafemina R, Balint J. Adoptive transfer of immunity from mice immunized with ribosomes or live yeast cells of Histoplasrna capsulaturn. Infect. II771771117. 15(3), 789–795 (1977).
  • Gomez FJ, Gomez AM, Deepe GS Jr. Protective efficacy of a 62-kDa antigen, HIS-62, from the cell wall and cell membrane of Histoplasrna capsulaturn yeast cells. Infect. II771771117. 59(12), 4459–4464. (1991).
  • Gomez FJ, Allendoerfer R, Deepe GS Jr. Vaccination with recombinant heat shock protein 60 from Histoplasrna capsulaturn protects mice against pulmonary histoplasmosis. Infect. Immun. 63(7), 2587–2595 (1995).
  • Deepe GS Jr, Gibbons RS. Cellular and molecular regulation of vaccination with heat shock protein 60 from Histoplasrna capsulaturn. Infect. II771771117. 70(7), 3759–3767 (2002).
  • Scheckelhoff M, Deepe GS Jr. The protective immune response to heat shock protein 60 of Histoplasrna capsulaturn is mediated by a subset of V 8.1/8.2+ T-cells. j I177177111701. 169(10), 5818–5826 (2002).
  • Deepe GS Jr, Gibbons R, Brunner GD, Gomez FJ. A protective domain of heat shock protein 60 from Histoplasrna capsulaturn. J. Infect. Dis. 174(4), 828–834. (1996).
  • Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS Jr, Casadevall A. Antibodies to a cell surface histone-like protein protect against Histoplasrna capsulaturn. j Clin. Invest. 112(8), 1164–1175 (2003).
  • •Reveals the utility of antibody-mediated therapeutic vaccination for an intracellular pathogen.
  • Klein BS, Vergeront JM, Weeks RJ et al. Isolation of Blastornyces derrnatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. N Engl. J Med. 314(9), 529–534 (1986).
  • Klein BS, Sondel PM, Jones JM. WI-1, a novel 120-kDa surface protein on Blastornyces derrnatitidis yeast cells, is a target antigen of cell-mediated immunity in human blastomycosis. Infect. Immun. 60(10), 4291–4300 (1992).
  • Brandhorst TT, Wuthrich M, Warner T, Klein B. Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis. J Exp. Med. 189(8), 1207–1216 (1999).
  • Klein BS, Jones JM. Purification and characterization of the major antigen WI-1 from Blastornyces derrnatitidis yeasts and immunological comparison with A antigen. Infect. II771771117. 62(9), 3890–3900 (1994).
  • Hogan LH, Josvai S, Klein BS. Genomic cloning, characterization, and functional analysis of the major surface adhesin WI-1 on Blastornyces derrnatitidis yeasts. J. Biol. Chem. 270(51), 30725–30732 (1995).
  • Wuthrich M, Chang WL, Klein BS. Immunogenicity and protective efficacy of the WI-1 adhesin of Blastornyces dennatitidis Infect. II771771117. 66(11), 5443–5449 (1998).
  • Wuthrich M, Filutowicz HI, Klein BS. Mutation of the WI-1 gene yields an attenuated Blastornyces derrnatitidis strain that induces host resistance. J Clin. Invest. 106(11), 1381–1389 (2000).
  • Wuthrich M, Filutowicz HI, Warner T, Deepe GS Jr, Klein BS. Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T-cells: implications for vaccine development in immune-deficient hosts. J Exp. Med. 197(11), 1405–1416 (2003).
  • •• Demonstrates that vaccination with an attenuated microbe can confer protection independent of C1j4+ cells, thus implying that such vaccines may be useful for AIDS patients.
  • Kirkland TN, Finley F, Orsborn KI, Galgiani JN. Evaluation of the proline-rich antigen of Coccidioides irnrnitis as a vaccine candidate in mice. Infect. Immun. 66(8), 3519–3522 (1998).
  • Jiang C, Magee DM, Quitugua TN, Cox RA. Genetic vaccination against Coccidioides irnrnitis: comparison of vaccine efficacy of recombinant antigen 2 and antigen 2 cDNA. Infect. Immun. 67(2), 630–635 (1999).
  • Peng T, Orsborn KI, Orbach MJ, Galgiani JN. Proline-rich vaccine candidate antigen of Coccidioides irnrnitis. conservation among isolates and differential expression with spherule maturation. J Infect. Dis. 179(2), 518–521 (1999).
  • Peng T, Shubitz L, Simons J et al. Localization within a proline-rich antigen (Ag2/PRA) of protective antigenicity against infection with Coccidioides irnrnitis in mice. Infect. Immun. 70(7), 3330–3335 (2002).
  • Li K, Yu JJ, Hung CY, Lehmann PF, Cole GT. Recombinant urease and urease DNA of Coccidioides irnrnitis elicit an immunoprotective response against coccidioidomycosis in mice. Infect. Immun. 69(5), 2878–2887 (2001).
  • Delgado N, Xue J, Yu JJ, Hung CY, Cole GT. A recombinant 13–1,3-glucanosyltransferase homolog of Cocddioides posadasii protects mice against coccidioidomycosis. Infect. II771771117. 71(6), 3010–3019 (2003).
  • Ivey FD, Magee DM, Woitaske MD, Johnston SA, Cox RA. Identification of a protective antigen of Coccidioides irnrnitis by expression library immunization. Vaccine 21(27-30), 4359–4367 (2003).
  • Stringer JR, Edman JC, Cushion MT, Richards FF, Watanabe J. The fungal nature of Pneurnocystis. J Med. Vet. Mycol. 30 (Suppl. 1), 271–278 (1992).
  • Totet A, Duwat H, Magois E et al. Similar genotypes of Pneurnocystisjirovecii in different forms of Pneurnocystis infection. Microbiology 150(5), 1173–1178 (2004).
  • Gigliotti F, Hughes WT. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneurnocystis carinii pneurnonitis in animal models. J Invest. 81(6), 1666–1668 (1988).
  • Gigliotti F, Haidaris CG, Wright TW, Harmsen AG. Passive intranasal monoclonal antibody prophylaxis against murine Pneurnocystis carinii pneumonia. Infect. II771771117. 70(3), 1069–1074 (2002).
  • Roths JB, Sidman CL. Both immunity and hyperresponsiveness to Pneurnocystis carinii result from transfer of CD4+ but not CD8+ T-cells into severe combined immunodeficiency mice. J Clin. Invest. 90(2), 673–678 (1992).
  • Smulian AG, Sullivan DW, Theus SA. Immunization with recombinant Pneurnocystis carinii p55 antigen provides partial protection against infection: characterization of epitope recognition associated with immunization. Microbes Infect. 2(2), 127–136 (2000).
  • Theus SA, Smulian AG, Steele P, Linke MJ, Walzer PD. Immunization with the major surface glycoprotein of Pneurnocystis carinii elicits a protective response. Vaccine 16(11-12), 1149–1157 (1998).
  • Pascale JM, Shaw MM, Durant PJ et al. Intranasal immunization confers protection against murine Pneurnocystis carinii lung infection. Infect. Immun. 67(2), 805–809 (1999).
  • Zheng M, Shellito JE, Marrero L et al. CD4+ T-cell-independent vaccination against Pneurnocystis carinii in mice. J Clin. Invest. 108(10), 1469–1474 (2001).
  • ••Demonstrates that vaccines for AIDS-related pathogens can be developed that will not require CD4+ cells.
  • Taborda CP, Nakaie CR, Cilli EM et al. Synthesis and immunological activity of a branched peptide carrying the T-cell epitope of gp43, the major exocellular antigen of Paracoccidioides brasiliensis. Scand. j I17717711fla 59(1), 58–65 (2004).
  • Pinto AR, Puccia R, Diniz SN, Franco MF, Travassos LR. DNA-based vaccination against murine paracoccidioidomycosis using the gp43 gene from Paracoccidioides brasiliensis. Vacdne 18(26), 3050–3058 (2000).
  • Diniz SN, Reis BS, Goes TS et al. Protective immunity induced in mice by FO and FII antigens purified from Paracoccidioides brasiliensis. Vaccine 22(3-4), 485–492 (2004).

Websites

  • NeuTec Pharma Plc www.neutecpharma.com Accessed November, 2004.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.